Back to today’s briefing

Story perspectives

Novo Nordisk Patent Expiration: Generics Slash Prices to INR1,500

3/20/2026

50 5 Full Breakdown

Summary

Story summary

Novo Nordisk's semaglutide patent expiration will enable over 40 local manufacturers to launch generics, potentially driving monthly prices from 11,000 rupees to as low as 1,500 rupees.
The shift is intended to broaden access beyond affluent urban areas.
Concerns exist about potential misuse and confusion among prescribers due to the influx of brands.
Atrogi is testing a new weight-loss drug, ATR-258, which promises muscle gain alongside fat loss.

1 of 1

Story summary

Novo Nordisk's semaglutide patent expiration will enable over 40 local manufacturers to launch generics, potentially driving monthly prices from 11,000 rupees to as low as 1,500 rupees.
The shift is intended to broaden access beyond affluent urban areas.
Concerns exist about potential misuse and confusion among prescribers due to the influx of brands.
Atrogi is testing a new weight-loss drug, ATR-258, which promises muscle gain alongside fat loss.